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Purpose: Smoking represents a primary risk factor for the development of urothelial carcinoma (UC) and a relevant factor impact-
ing UC-specific prognosis. Data on the accordant knowledge of UC-patients in this regard and the significance of physicians in the 
education of UC-patients is limited.
Materials and Methods: Eighty-eight UC-patients were enrolled in a 23-items-survey-study aimed to analyse patient knowledge 
and awareness of their tumor disease with smoking along with physician smoking cessation counselling.
Results: The median age of the study patients was 69 years; 26.1% (n=23), 46.6% (n=41), and 27.3% (n=24), respectively, were 
non-smokers, previous, and active smokers. Exactly 50% of active smokers reported a previous communication with a physician 
about the association of smoking and their tumor disease; however, only 25.0% were aware of smoking as main risk factor for UC 
development. Merely 33% of the active smokers had been prompted directly by their physicians to quit smoking. About 42% of ac-
tive smokers had received the information that maintaining smoking could result in a tumor-specific impairment of their progno-
sis. Closely 29% of active and about 5% of previous smokers (during the time-period of active smoking) had been offered support 
from physicians for smoking cessation. No association was found between smoking anamnesis (p=0.574) and pack-years (p=0.912), 
respectively, and tumor stage of UC.
Conclusions: The results of this study suggest that the medical conversation of physicians with UC-patients about the adverse sig-
nificance of smoking is limited. Implementation of structured educational programs for smoking cessation may be an opportunity 
to further enhance comprehensive cancer care.
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Based on 2013 estimations of  the World Health 
Organization, about one billion people worldwide were active 
smokers and around six million people died from diseases 
caused by smoking, including mainly cardiovascular and 
pulmonary diseases as well as cancer [1]. Epidemiological 
studies on upper tract urothelial carcinoma (UTUC) and 
urothelial carcinoma of the bladder (UCB) have identified 
several etiological risk factors, with cigarette smoking and 
exposure to certain occupational agents being of highest 
importance [2-4]. Out of the more than 60 carcinogens and 
free reactive oxygen radicals, the main relevant metabolites 
responsible for urothelial carcinoma (UC) development 
are not reliably identified yet; however, it is proven that 
smoking impairs cellular DNA repair mechanisms, which 
subsequently diminishes the body’s defence mechanisms (host 
response) against carcinogens [4,5]. 
In 2013, 382,700 new cases of  UCB were diagnosed 
worldwide and they were 143,000 associated deaths [1,6]. 
In half of UCB-patients smoking is the most relevant risk 
factor; while studies have shown that smoking cessation in 
UCB-patients significantly reduces the risk for recurrence 
[7-10]. Based on the results of a recent meta-analysis of 83 
studies, the relative risk for developing UCB was 2.58 (95% 
confidence interval [CI], 2.37 to 2.80) in all smokers, with 
active smokers having a relative risk of 3.47 (95% CI, 3.07 to 
3.91) while the relative risk of former smokers was 2.04 (95% 
CI, 1.85 to 2.25) [1]. In addition, cancer-specific mortality was 
higher in smokers (active and previous smokers combined) 
by 47% (95% CI, 24% to 75%) [1]. 
Finally, there is an abundance of evidence that physicians 
should provide smoking prevention and cessation counselling 
in a prophylactic manner for promotion and maintenance of 
personal health. The time of UC diagnosis has been shown 
to be a “teachable moment,” highlighting an opportunity for 
urologists and oncologists to recommend rigorous smoking 
cessation to enhance the individual tumor-specific prognosis. 
To date, a paucity of data exists on the knowledge of UC-
patients regarding the association of their tumor disease 
with smoking habits. Furthermore, limited studies have 
investigated which communication between doctors and 
patients on this critical point is undertaken in clinical 
routine and which resources and aids for smoking cessation 
are offered by physicians (and mainly urologists) to UC-
patients who are active smokers. In a survey conducted at 
the Johns Hopkins Hospital in Baltimore by Guzzo et al. 
[11] on 71 UCB-patients only 84.5% were aware of smoking 
as a risk factor for UCB development and 59% of active 
and previous smokers were advised by their urologists to 
quit smoking or not to restart again. Studies on this topic 
conducted in Europe are yet pending.
The aim of the present bicentric survey study was to 
analyze knowledge and awareness level of  UC-patients 
concerning the association of  their tumor disease with 
smoking. Furthermore, we aimed to evaluate the association 
of smoking habits and tumor stage. Based on the analysis of 
available services for smoking cessation and the time volume 
of accordant informative conversations, also the status quo 
concerning current implementation of elementary and self-
financing conversations of physicians with their patients 
will be displayed. 
MATERIALS AND METHODS
1. Study conduction
A survey comprising 23 items was developed with the 
aim of assessing knowledge and awareness level of in-house 
patients with a histologically confirmed genitourinary 
malignancy (UTUC, UCB, renal, prostate, and testicular 
cancer) on the association of  their tumor disease (and 
other urological tumors) and cigarette smoking (concerning 
tumor development and prognosis). Selective questions 
were integrated to assess 1) the manner and the extent of 
medical informative conversations conducted in this regard 
and 2) the resources provided to patients for smoking 
interruption or cessation. Previous smokers were asked for 
their individual reasons that had led them to quit smoking, 
and current smokers were queried for their concrete further 
intention regarding cigarette consumption. Prior to study 
initiation the survey was validated on 25 patients with 
uro-oncological diseases to confirm comprehensibility and 
clarity of questions. Study inclusion criteria were histologic 
confirmation of  a urologic malignancy, the capability of 
informed consent, and an age of at least 18 years. The study 
title was defined as “Knowledge of tumor patients regarding 
the Risk Association of  smoking habits and Urological 
Tumors” (KRAUT study); ethical committee approval of the 
State Chamber of Medicine in Brandenburg was obtained 
(BLAEK-EK no. 13012). Written informed consent was 
obtained from all patients before enrolment. The study 
was conducted between September 1st 2013 and December 
31st 2014 in two urological departments (Caritas St. Josef 
Medical Center, University of  Regensburg; St. Elisabeth 
Hospital Straubing; Academic Teaching Hospital of  TU 
Munich University) [12,13]. In addition to the 23 items of the 
survey, demographic, clinical, and oncological information 
was obtained from all enrolled 258 patients (UC, n=88; renal 
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cancer, n=34; prostate cancer, n=124; testicular cancer, n=12).
2. Study group and study criteria
The study group comprised 88 patients with histologically 
confirmed UC (UCB, n=85; UTUC, n=3), who underwent in-
house treatment in two urological departments (Straubing, 
n=42; Regensburg, n=46). During the assessment period 256 
(76+180) UC-patients (coded as C65-67) were treated with an 
in-house duration of >1 day, so that overall 34.4% of possible 
patients could be included. They study survey is shown 
in the Supplementary material. Patient related criteria 
included age, gender, body mass index (BMI), and tumor 
manifestation (within three months since diagnosis versus 
tumor recurrence). Furthermore, clinical-pathological tumor 
stage was assessed in a dichotomized manner (<c/pT2, c/pN0, 
c/pM0 vs. muscle-invasive and/or metastasized tumor stages).
3. Statistical analysis
Continuous variables are displayed with medians and 
interquartile ranges (IQR). To analyze differences in the 
distribution of continuous parameters between non-smokers 
and smokers (summarized as active and previous smokers), 
the Kruskal-Wallis-H Test was applied. The distribution of 
categorical variables in different groups was compared by 
chi-square test. If reasonable, descriptive results of nominal 
scaled items were displayed in summary. Two multivariate 
logistic regression models (MLRM) were built to assess the 
independent impact of smoking as dependent dichotomized 
variables on tumor stage with one model adjusted for the 
smoking status variable and the second model including the 
number of pack-years.
The preferable sample size to achieve a statistical 
power of 0.8 to 0.85 for this study was neither reached a 
priori nor post-hoc, as no information was available on the 
putative effect size for the impact of smoking on the binary 
categorized tumor stage (see above). This information would 
have potentially been extractable for cancer-specific mortality 
analyses from recent meta-analyses; however, for the advised 
surrogacy analyses of  the present study (comparison of 
tumor stages) this information was not provable [1,9].
For data analysis IBM SPSS Statistics ver. 24.0 (IBM Co., 
Armonk, NY, USA) was applied. The p-values provided are 
two-sided with a level of significance defined as p<0.05 for 
all tests conducted.
RESULTS
Eighty-eight UC-patients (85 and 3 with UCB and 
UTUC, respectively) were enrolled in the study, of which 
23 (26.1%), 41 (46.6%), and 24 (27.3%), respectively, were non-
smokers, previous smokers, and active smokers. Descriptive 
patient characteristics and comparison between non-smokers 
and smokers are displayed in Table 1. The median age of 
the study group was 69 years (IQR, 61 to 73.8 years) with 
no significant difference between non-smokers and (active 
as well as previous) smokers (p=0.102). The median age of 
active and previous smokers was significantly different (64 
years vs. 70 years, p=0.002), while there was no significant 
difference in the median number of  pack-years between 
both groups (29.3 vs. 29.2, p=0.946). Forty-nine patients (55.7%) 
had a primary UC at the time of study conduction (initial 
or subsequent treatment within three months of diagnosis), 
18 patients (20.5%) presented with muscle invasive and/or 
metastatic disease.
Table 1. Distribution of clinical and oncological criteria in 88 patients with UC of the renal pelvis or bladder, distributed in non-smokers and smok-
ers (active and previous smokers)
Study criteria Study group (n=88) Non-smokers (n=23) Smokers (n=65) p-value
Patient age (y) 69 (61–73.8) 72 (61–77) 67 (60.5–73) 0.102
Male gender 71 (80.7) 20 (87.0) 51 (78.5) 0.542
Body mass index (kg/m2) 26.7 (24.7–30) 26.4 (24.1–30) 26.8 (24.8–30.2) 0.683
Organ distribution of UC 0.564
   Renal pelvis 3 (3.4) 0 (0.0) 3 (4.6)
   Urinary bladder 85 (96.6) 23 (100.0) 62 (95.4)
Disease status 0.808
   Primary (≤3 months sD) 49 (55.7) 12 (52.2) 37 (56.9)
   Recurrent disease and/or >3 months sD 39 (44.3) 11 (47.8) 28 (43.1)
Tumor stage 0.772
   <c/pT2N0M0 70 (79.5) 19 (82.6) 51 (78.5)
   ≥c/pT2 and/or metastatic stage 18 (20.5) 4 (17.4) 14 (21.5)
Values are presented as median (range) or number (%).




Exactly 64.9% of patients who responded to these questions 
(50/77) considered it possible that cigarette consumption could 
generally impact UCB development. Forty of 67 patients 
(59.7%) considered it as conceivable or proven that cigarette 
consumption impacts UCB prognosis. In comparison, 100% 
of patients who responded to both questions considered the 
impact of  smoking on the development and/or prognosis 
of bronchial carcinoma as probable or proven. There was a 
significant agreement in the judgement of those patients, who 
estimated the impact of smoking on UC development and 
prognosis as possible or proven (p<0.001).
Exactly 32.3% of  smokers (21/65) confirmed to have 
altered their cigarette consumption due to their tumor 
disease. Ten of these 21 patients had quit smoking after 
UC diagnosis, furthermore 11 had reduced consumption. 
Additionally, 31 patients had stopped smoking for various 
reasons unrelated to their tumor disease. Fifteen of  24 
active smokers (62.5%) confirmed that they would have 
stopped smoking immediately if they had known about a 
possible association with UC development and prognosis. 
Only six of 24 active smokers (25.0%) and 10 of 41 previous 
smokers (24.4%) considered smoking the main cause of UC 
development.
Eight of  24 active smokers (33.3%) had been directly 
advised by their treating physicians to quit smoking due to 
their tumor disease and of 41 previous smokers, 12 patients 
(29.3%) had received a clear recommendation by their 
physician(s) to stop smoking due to their tumor disease 
or to not restart smoking again. Ten of 24 active smokers 
(41.7%), 17 of 41 previous smokers (41.5%) and 5 of 23 non-
smokers (21.7%) had an accordant informative conversation 
with their urologist concerning the association of cigarette 
consumption and UC prognosis (further 8.3%, 7.3% and 
4.3%, respectively, received this information exclusively by 
physicians from other medical specialties). On the other 
hand, of 24 active and 41 previous smokers 7 (29.2%) and 
13 (31.7%) patients indicated that they don’t require an 
informative conversation with physicians or don’t consider 
such conversation as necessary. Seven active smokers (29.2%) 
and 2 previous smokers (4.9%) had been offered services for 
smoking cessation. Nine patients only of the entire study 
group (10.2%) indicated that the cumulative time used for 
accordant informative conversations on the association of 
cigarette smoking with urological tumor diseases comprised 
10 minutes or more. 
Exactly 17.4% (4/23), 24.4% (10/41), and 16.7% (4/24) of non-
smokers, previous smokers, and active smokers, respectively, 
presented with muscle-invasive and/or metastatic disease 
(group comparison, p=0.772). Both smoking anamnesis (odds 
ratio [OR], 1.46; p=0.574) and cumulative dose/pack-years 
(OR, 1.00; p=0.912) didn’t have an independent impact on 
tumor stage (Table 2). BMI had a significant impact on this 
Fig. 1. Results of multivariate regression analysis for the impact of smoking status (active or previous smokers vs. non-smoker) on tumor stage 


















0 1 2 3 4 5 6 7
Table 2. Multivariate logistic regression model to evaluate the independent impact of different criteria on the presences of muscle-invasive and/
or metastatic disease 
Study criteria Model 1 p-value Model 2 p-value
Patient age (y) 1.04 (0.97–1.11) 0.305 1.03 (0.97–1.11) 0.336
Female gender (ref.: male gender) 1.71 (0.43–6.81) 0.444 1.75 (0.44–6.99) 0.429
Body mass index (kg/m2) 0.82 (0.71–0.96) 0.012 0.82 (0.71–0.96) 0.012
Smoker (ref.: non-smoker) 1.46 (0.39–5.44) 0.574 -
Pack-years (y) - 1.00 (0.98–1.03) 0.912
Values are presented as odds ratio (95% confidence interval).
Model 1 with inclusion of smoking status (active and previous smokers vs. non-smokers), Model 2 with inclusion of pack-years.
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endpoint with every increase in BMI per kg/m² reducing the 
possibility of muscle-invasion and/or metastatic tumor stage 
by 18% (95% CI, 4% to 29%; p=0.012) (Table 2, Fig. 1).
DISCUSSION
Health care providers are urged to advise their patient 
population about the significant impact of smoking on cancer 
development and the associated increase of cardiovascular 
and pulmonary morbidity and mortality. Programs and 
initiatives to increase the awareness in this regard should 
aim to counsel non-smokers to maintain their abstinence and 
to recommend smokers to quit smoking. Besides impairment 
of different organ functions (and subsequently potentially 
also the individual capability for surgery and anaesthesia), 
smoking contributes to UC, renal, and penile cancer 
development as well as impacts prognosis of UC and prostate 
cancer patients [14,15]. For UC (especially UCB) the evidence 
is consistent and reliable: smoking represents the main risk 
factor for cancer development and is additionally associated 
with an impairment of the cancer-specific prognosis [1-10]. 
Furthermore, the association between smoking duration 
and intensity with erectile dysfunction is clearly proven [16]. 
Taken together, these smoking related genitourinary diseases 
place the urologist in a unique position to provide smoking 
cessation guidance. 
Which conclusions should urologists draw by the above-
mentioned insights and the results of our survey? About 74% 
of study participants with histologically confirmed UC were 
active or previous smokers; for both groups of smokers about 
30 pack-years were calculated on average with no significant 
difference between both groups. Although 50% of patients 
who were active smokers at the time of diagnosis had a 
conversation with their physician(s) about the correlation 
of their tumor disease with smoking, only 25% were aware 
of  smoking as main risk factor of  UC development. One 
third of active smokers only were directly asked by their 
physicians to quit smoking and 42% of patients belonging 
to this group were informed that maintenance of smoking 
could result in a tumor-specif ic impairment of  their 
prognosis. 29% of active smokers and 5% of previous smokers 
only were offered support for smoking cessation by their 
physicians during their active smoking period. Also, only 10% 
of the entire study group had informative and educational 
conversations about the potential negative impact of 
smoking of cumulatively at least 10 minutes. Based on the 
results of this survey, it appears that urologists inadequately 
communicate (as it concerns time and content) with UC-
patients about the adverse impact of  smoking. Further 
studies have confirmed this observation and indicate a need 
for optimization in this regard on a worldwide level [11,17-
21]. In a study by Bjurlin et al. [18] on 535 in-house urological 
patients with different diseases 25% of patients considered 
smoking as relevant for UCB development. The study 
results published by Westhoff et al. [19] on 1,735 long-term 
survivors with UCB recorded in the Netherlands Cancer 
Registry between 2007 and 2012 even showed that only 10% 
considered smoking as causative for UCB development. In a 
2013 national survey of urologists, Bjurlin et al. [22] indicated 
that urologists have the responsibility to counsel their 
patients by structured education and provision of specific 
support for smoking cessation to strictly quit smoking. How 
this “teachable moment” at the time of  cancer diagnosis 
could be used to motivate patients to completely change 
their lifestyle (including smoking reduction or cessation) 
has been addressed by a structured program introduced by 
Lee et al. [23]. In this regard, urologists should also be aware 
of their function as primary contact for UC-patients and 
should aim to extend their core competence in diagnostics 
and treatment of  this disease also to aspects of  lifestyle 
changes impacting the course of disease. 
Based on the results of our study we could not confirm 
an association between cigarette smoking and the presence 
of advanced tumor stages. 17.4% and 21.5%, respectively, of 
non-smokers and (active and previous) smokers had a tumor 
stage >c/pT1N0M0 (p=0.772). Based on two multivariable 
models neither smoking status (smoker vs. non-smoker) 
nor the cumulative smoking dose (based on pack-years) 
had an independent impact on tumor stage. Also, when 
this category was adapted (e.g., >c/pTaN0M0), smoking 
status and cumulative dose didn’t significantly impact this 
endpoint (results not shown). In contrast, larger studies 
with better definition of advanced UC stages could show 
an association with smoking and more aggressive tumors 
[24,25]. Interestingly, in the present study, BMI was the only 
criterion significantly impacting tumor stage, while every 
increase in BMI per kg/m² reduced the risk of a muscle-
invasive and/or metastasized tumor stage by 18% (p=0.012). 
The international evidence is inconsistent in this regard, 
however, the association between a higher BMI and less 
advanced tumor stages has been described by other work 
groups as well [26,27]. 
Several limitations concerning the interpretation of our 
study need to be considered. In addition to the overall limited 
number of patients participating in this survey, only 34.4% 
of possible UC-patients could be included. This is remarkable, 
as this selection bias (participants vs. responders) could 




significant differences could fail due to limited statistical 
power (see also MATERIALS AND METHODS section). 
Since the KRAUT study was developed for urological 
cancer patients in general, but not specifically for UC-
patients, clinical and oncological criteria gathered in the 
survey population represent a compromise to cover different 
urological tumors; desired UC specific criteria (treatment 
modalities) and general criteria (occupational exposure, 
educational status, assignment to different referring medical 
specialties) were not collated. Due to the lack of validated 
questions in this specific setting, the items of this study 
were self-designed. However, prior to study start, all survey 
questions were validated in structured interviews with 
25 uro-oncological patients in one hospital (St. Elisabeth 
Hospital Straubing, Germany). Furthermore, this study was 
conducted as a survey, hence, honesty of patients concerning 
their smoking habits is desired, but not a precondition which 
can be postulated. In addition, not all items were responded 
by all patients (whereas all questionnaires were controlled 
for plausibility by both data responsible persons [MD, OM] 
together. Based on the evaluated questions, we could not 
generate findings about secondary smoking exposure, which 
could impact study results (especially in cases of long-term 
exposition). Patients included in the KRAUT study were not 
further followed for their oncological course. 
CONCLUSIONS
The knowledge of UC-patients concerning the general 
association of  their tumor disease with smoking seems 
to be limited. Comparable to other tobacco associated 
cancers, the time of  UC diagnosis may allow physicians 
to use this time-point as a “teachable moment” in order to 
educate patients in a structured manner and to offer active 
smokers sufficient support for smoking cessation. Urologists 
remain in a unique position and should actively counsel 
patients concerning possible lifestyle changes, ultimately 
strengthening their role as primary partners of UC-patients 
in the comprehensive therapeutic management of UC. 
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Supplementary material. Collection of patient related criteria and KRAUT survey with all items (Please consider: 
the KRAUT study was not specifically developed for UC-patients, but for different urological tumor entities) 
KRAUT – Questionnaire A (to be completed by the physician) 
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Patient and tumor related questions 
1 Height (cm)  
2 Weight (kg)  
3 Date of birth (dd/mm/yyyy)  
4 Date of survey (dd/mm/yyyy)  
5 Date of initial diagnosis of tumor disease (dd/mm/yyyy)  
6 Organ affected) by urological tumor (multiple options possible) 
 A Renal parenchyma 
 B Renal pelvis 
 C Ureter 
 D Urinary bladder 
 E Prostate 
 F Urethra 
 G Testicles 
 H Penis 
 I Adrenal gland 
7 Histology of the urological tumor (only one option possible) 
 A Adenocarcinoma 
 B Squamous cell carcinoma 
 C Transitional cell carcinoma 
 D Seminomatous germ cell cancer 
 E Non-seminomatous germ cell cancer 
 F Clear cell renal cell carcinoma 
 G Non-clear cell renal cell carcinoma 
 H Neuroendocrine carcinoma 
 I Sarcoma 
 J Benign tumor 
 K Other histology 
8 TNM Classification of the tumor according to the 7th edition  
(one answer necessary at each pT, c/pN and c/pM) 
 A pTa/CIS 
 B pT1 
 C pT2 
 D pT3 
 E pT4 
 F c/pN0 
 G c/pN+ 
 H c/pM0 
 I c/pM1 
 J Benign tumor 
 K pT-stage is not applicable to this histology 
KRAUT – Questionnaire B (to be completed by the patient) 
1       Please proceed with the next page 
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Patient and tumor related questions 
1 Is this the first time you take part in this survey?
 A No, I have never taken part in this survey
 B Yes, I have already taken part in this survey, but I still do not feel sufficiently informed 
about smoking and its relationship with urological tumor occurence and development. 
 C Yes, I have already taken part in this survey, and I believe I am partially better informed 
about smoking and its relationship with urological tumor occurence and development. 
 D Yes, I have already taken part in this survey, and I believe I am much better informed now 
about smoking and its relationship with urological tumor occurence development. 
2 Do you smoke? (multiple answers possible)
 A I am a non-smoker (neither cigarettes nor tobacco in any other way).
 B I smoke cigarettes. 
 C I am a former smoker. 
 D I am an occasional smoker (<19 cigarettes per month).
 E I occasionally (not regularly) smoke cigars and/or pipe.
 F I smoke cigars and/or pipe every day.
Answer the following two questions only if you smoke cigarettes (if not, please continue with question 
no. 5) 
3 I smoke cigarettes and in total, I have been smoking for xx years (If there was an intermittent period 
of abstinence, please deduct those years) 
 A Years  
4 I smoke cigarettes and I regularly smoke an average of xxx cigarettes per day. 
 A Cigarettes  
Answer the following three questions only if you are a former smoker (if not continue, please continue 
with question no. 8) 
5 I am a former smoker. I have smoked for xx years.
 A Years  
6 I am a former smoker. I have smoked on average xxx cigarettes per day.
 A Cigarettes  
7 I have quit smoking xx years ago. 
 A Years  
8 Do you smoke? (multiple answers possible)
 A I am a non-smoker. 
 B I have quit smoking due to my tumor disease.
 C I reduced my level of smoking due to my tumor disease.
 D I am currently planning to stop smoking due to my tumor disease.
 E I have changed my smoking habits due to other disease(s) and not because of my tumor 
disease. 
 F I have changed my smoking habits, but this was neither influenced by my tumor disease 
nor other diseases.  
 G I continue my smoking habits as before and onset of tumor disease did not impact my 
tumor habits. 
  
KRAUT – Questionnaire B (to be completed by the patient) 
2       Please proceed with the next page 
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9 Have you ever had an informational conversation about the possibility that the occurrence or 
development of your tumor might be related to smoking? (multiple options possible, non-
smokers should answer as well) 
 A No. 
 B Yes, with my family doctor or an internist. 
 C Yes, with a resident urologist. 
 D Yes, with a urologist in a hospital. 
 E Yes, with a doctor not listed under bullet point B-D. 
 F Yes, with other medical staff (e.g. a nurse). 
10 Have you ever had an informational talk about the possibility that the course (the prognosis) of 
your tumor disease might be influenced by smoking? (multiple options possible, non-smokers 
should answer as well, too) 
 A No. 
 B Yes, with my family doctor or an internist. 
 C Yes, with a resident urologist. 
 D Yes, with a urologist in hospital. 
 E Yes, with a doctor not listed under bullet point B-D. 
 F Yes, with other medical staff (e.g. a nurse). 
11 Have you ever been asked by a doctor directly to quit or reduce smoking or not to start smoking 
(in case you are a non-smoker) due to your current tumor disease? 
 A No. 
 B Yes. 
12 Which of the following statements apply to you? (two answers necessary, one at A-C, another 
at D-E) 
 A The occurrence of my current tumor disease is not related to smoking as I have never 
smoked. 
 B I believe that the occurrence of my tumor disease is not related to smoking, although 
I am a smoker or former smoker. 
 C I am a smoker or former smoker and believe that smoking has/had an influence on 
the occurrence of my tumor disease. 
 D I believe that the course of disease (prognosis) of my tumor disease is not influenced 
by me due to continuation of smoking or starting to smoke. 
 E I believe that the course of disease (prognosis) of my current tumor disease is 
influenced by me due to continuation of smoking or starting to smoke 
13 If you had known about the relationship between the urological tumor disease you are 
diagnosed with and smoking before you were affected, would you have stopped smoking? 
 A I am a non-smoker and I don’t/didn´t smoke because I would like to prevent tumor 
occurrence and development. 
 B I am a non-smoker, but for other reasons than fear of a possible tumor disease. 
 C I am a smoker and I would have stopped smoking. 
 D I am a smoker and I would not have stopped smoking. 
 E I am a former smoke and I have quit smoking for this reason. 
 F I am a former smoker, but this was not the reason why I stopped. 
KRAUT – Questionnaire B (to be completed by the patient) 
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Do you think that the following statements concerning possible relationships between smoking and 
different urological tumor types are correct? Following you find three hypotheses concerning the 
development of tumors and three hypotheses concerning the course of the tumor disease; only one 
statement per tumor type is correct. So please tick only one cross per type of tumor and 
development and one per type of tumor and course of disease. 
14 Smoking is one of the main causes for the development of this tumor disease: 
 A Lung cancer 
 B Bladder cancer 
 C Kidney cancer 
 D Prostate cancer 
 E Penile cancer 
 F Testicular cancer 
15 A (non-proven) relationship between smoking and the development of this tumor disease is 
being discussed: 
 A Lung cancer 
 B Bladder cancer 
 C Kidney cancer 
 D Prostate cancer 
 E Penile cancer 
 F Testicular cancer 
16 There is no relationship between smoking and the development of this tumor disease: 
 A Lung cancer 
 B Bladder cancer 
 C Kidney cancer 
 D Prostate cancer 
 E Penile cancer 
 F Testicular cancer 
17 There is a relationship between smoking and the course of disease of this tumor: 
 A Lung cancer 
 B Bladder cancer 
 C Kidney cancer 
 D Prostate cancer 
 E Penile cancer 




KRAUT – Questionnaire B (to be completed by the patient) 
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18 A (non-proven) relationship between smoking and the course of disease of this tumor is being 
discussed: 
 A Lung cancer 
 B Bladder cancer 
 C Kidney cancer 
 D Prostate cancer 
 E Penile cancer 
 F Testicular cancer 
19 There is no relationship between smoking and the course of disease of this tumor: 
 A Lung cancer 
 B Bladder cancer 
 C Kidney cancer 
 D Prostate cancer 
 E Penile cancer 
 F Testicular cancer 
20 Do you feel well informed about the potential relationship between your tumor disease and 
smoking (This questions should also be answered by non-smokers, multiple answers possible) 
 A Information is not necessary, as there is no relationship between smoking and my 
tumor disease. 
 B Yes, I feel well informed. The information provided by media, public education, and 
my physicians is sufficient. 
 C No, I don´t feel well informed. There is too few information provided by media and 
public education. 
 D No, I don´t feel well informed. There is too few information provided by my doctors. 
21 Have you ever been offered any support by your doctors to help you stop smoking? 
 A I am a non-smoker. 
 B I am a smoker and I have never been offered any of the aids listed below (C-F) 
 C Yes, informational brochures by my family doctor/internist have been provided. 
 D Yes, informational brochures by my urologist have been provided. 
 E Yes, nicotine replacement therapies and other therapies to change my smoking 
habits have been suggested or provided by my family doctor/internist. 
 F Yes, nicotine replacement therapies and other therapies to change my smoking 
habits have been suggested or provided by my urologist. 
22 Altogether how much time did your doctors spent to inform you about the possible relationship 
between smoking and your urological tumor disease? 
 A I have never talked to my doctors about this topic. 
 B Added together, less than 5 minutes. 
 C Added together, 5-10 minutes. 
 D More than 10 minutes. 
23 In case the conversation took more than 10 minutes (question 22), how many minutes did it 
last?  
 A Minutes  
Thank you very much for your participation! 
